Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Mologen gets EC grant to develop DNA vaccine
January 2009
SHARING OPTIONS:

BERLIN—Mologen AG announced it will receive funding from the European Commission within the 7th European Research Framework Program for the development of a prophylactic and therapeutic DNA vaccine against visceral leishmaniasis in humans, a severe and often fatal infectious disease. To this end, the consortium will develop a MIDGE-based vaccine for humans, evaluate its immunogenicity in human cell culture systems, its efficacy in animal models, and establish its safety in standardised preclinical studies. The total funding for the project amounts to E3.0 million, of which Mologen will receive E1.2 million during the 3-year project period, starting January 2009. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.